Literature DB >> 3900230

Distribution of a cross-species melanoma-associated antigen in normal and neoplastic human tissues.

P Natali, A Bigotti, R Cavalieri, S Wakabayaski, M Taniguchi, S Ferrone.   

Abstract

In previous studies the monoclonal antibody (MoAb) M2590 elicited in C57/BL6 mice with the syngeneic melanoma cell line B16 has been shown to recognize a 31K glycoprotein expressed by human melanoma cell lines. The present study has shown that the MoAb M2590 cross-reacts with surgically removed benign and malignant lesions of melanocyte origin. The reactivity pattern of the MoAb M2590 with these lesions is different from that of the anti-high-molecular weight-melanoma associated antigen (HMW-MAA) MoAb 225.28S, of the anti-115K MAA MoAb 345.134S, and of the anti-100K MAA MoAb 376.96S, which were elicited with human melanoma cell lines. In particular, the MoAb M2590 reacts with blue nevi. The MoAb M2590-defined MAA, like other types of MAA, is heterogeneous in lesions removed from different patients, in autologous lesions removed from different anatomic sites, and in cells within a lesion. The distribution of the MoAb M2590-defined MAA in normal tissues and in tumors of nonmelanocyte origin is broader than that of the HMW-MAA, but is similar to that of the 115K MAA and of the 100K MAA. The results of this investigation suggest that immunization with xenogeneic melanoma cells may broaden the range of specificity of antihuman MAA MoAbs and provide information about the phylogenetic evolution of MAAs.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3900230     DOI: 10.1111/1523-1747.ep12276944

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  6 in total

1.  A high molecular weight melanoma-associated antigen-specific chimeric antigen receptor redirects lymphocytes to target human melanomas.

Authors:  William R Burns; Yangbing Zhao; Timothy L Frankel; Christian S Hinrichs; Zhili Zheng; Hui Xu; Steven A Feldman; Soldano Ferrone; Steven A Rosenberg; Richard A Morgan
Journal:  Cancer Res       Date:  2010-04-15       Impact factor: 12.701

2.  B7-H3 targeted antibody-based immunotherapy of malignant diseases.

Authors:  Theodoros Michelakos; Filippos Kontos; Omar Barakat; Luke Maggs; Joseph H Schwab; Cristina R Ferrone; Soldano Ferrone
Journal:  Expert Opin Biol Ther       Date:  2020-12-21       Impact factor: 4.388

3.  In vivo safety profile of a CSPG4-directed IgE antibody in an immunocompetent rat model.

Authors:  Iwan P Williams; Silvia Crescioli; Heng Sheng Sow; Heather J Bax; Carl Hobbs; Kristina M Ilieva; Elise French; Giulia Pellizzari; Vivienne Cox; Debra H Josephs; James F Spicer; Sophia N Karagiannis; Silvia Mele
Journal:  MAbs       Date:  2020 Jan-Dec       Impact factor: 5.857

4.  CSPG4 Is a Potential Therapeutic Target in Anaplastic Thyroid Cancer.

Authors:  Caitlin E Egan; Dessislava Stefanova; Adnan Ahmed; Vijay J Raja; Jessica W Thiesmeyer; Kevin J Chen; Jacques A Greenberg; Taotao Zhang; Bing He; Brendan M Finnerty; Rasa Zarnegar; Moonsoo M Jin; Theresa Scognamiglio; Noah Dephoure; Thomas Fahey; Irene M Min
Journal:  Thyroid       Date:  2021-07-05       Impact factor: 6.506

Review 5.  Theranostic impact of NG2/CSPG4 proteoglycan in cancer.

Authors:  Pier Andrea Nicolosi; Alice Dallatomasina; Roberto Perris
Journal:  Theranostics       Date:  2015-02-15       Impact factor: 11.556

Review 6.  Chondroitin Sulfate Proteoglycan 4 and Its Potential As an Antibody Immunotherapy Target across Different Tumor Types.

Authors:  Kristina M Ilieva; Anthony Cheung; Silvia Mele; Giulia Chiaruttini; Silvia Crescioli; Merope Griffin; Mano Nakamura; James F Spicer; Sophia Tsoka; Katie E Lacy; Andrew N J Tutt; Sophia N Karagiannis
Journal:  Front Immunol       Date:  2018-01-10       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.